Latest Conference Articles

Amid Good Signs on Biosimilars, COVID-19 Upends Drug Purchasing Patterns

Mary Caffrey

April 20 2020

Douglas M. Long, MBA, vice president of Industry Relations for IQVIA, surveyed COVID-19's effects on the pharmaceutical marketplace as he kicked off AMCP eLearning Days, a webinar series held in place of the annual meeting of the Academy of Managed Care Pharmacy (AMCP).

AMCP Posters Demonstrate Value of Biosimilars

Skylar Jeremias

April 20 2020

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

Ruby Singh Previews the AMCP eLearning Days Virtual Meeting

April 17 2020

Ruby Singh, vice president for Education and Training, Academy of Managed Care Pharmacy (AMCP), speaks with Mary Caffrey about the upcoming AMCP eLearning Days, a virtual meeting that will take place April 20 to 24. AMCP's annual meeting was canceled due to coronavirus disease 2019 (COVID-19). This transcript is edited slightly for clarity.

Russia May Open the Spigot on Biosimilars

Skylar Jeremias

April 13 2020

Russia has rebuilt its pharmaceutical industry following the demise of the former Soviet-led government, and emerging companies such as Geropharm are looking for markets abroad.

Is Expanded Access a Route to Biosimilars Mired in Litigation?

Tony Hagen

March 23 2020

Legal and industry experts ponder whether expanded access to biosimilars is a way around patent thickets that slow the launch of approved biosimilars.

PhRMA: Federal Biosimilar Payment Policies Are Having a Positive Effect

Tony Hagen

March 4 2020

Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes that have increased biosimilar uptake and additional measures that could lead to greater use of biosimilars and savings for CMS and patients.

Amgen's Christl Says US Biosimilars Market Is on Solid Ground

Tony Hagen

March 3 2020

The US biosimilars market is showing healthy vital signs, said Leah Christl, Amgen’s executive director for global regulatory and research and development policy, in a talk kicking off the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California, while also reassuring the audience that her former FDA colleagues are still champions of their work.

Remove Roadblocks to Streamline the Biosimilar Approval Process, Industry Veteran Says

Tony Hagen

February 14 2020

Sarfaraz K. Niazi, PhD, a pharma industry veteran and consultant for biosimilar makers, discusses ins and outs of the approvals process that cause frustration and unnecessary expense.

Biosimilar Pipeline Congested by Patent Litigation Bottleneck

Tony Hagen

February 11 2020

The orphan drug market could see hefty biosimilar competition, based on revenue potential, and patent struggles need to be resolved before some biosimilars can come to market, according to a speaker reviewing the 2020 pipeline at the Specialty Therapies and Biosimilars Congress.

Pipeline Report: Oncology Biosimilars to Advance in 2020

Tony Hagen

February 10 2020

Biosimilars are starting to gain some traction in the marketplace, according to a speaker reviewing the 2020 pipeline at the Specialty Therapies and Biosimilars Congress.